5 March 2025: TRIAL UPDATE We’re excited to have now opened all Australian sites for the TROG 21.07 – SOCRATES HCC study, which is investigating the use of an advanced radiotherapy technique for early stage hepatocellular (HCC) cancer. With the opening of a clinical trial site at St George
4 March 2025: A decade on from the last participant completing treatment, the BIG 3-07/TROG 07.01 – DCIS trial is continuing to deliver valuable results. Led by TROG Cancer Research, the international, randomised phase III study aimed to improve the treatment outcomes of women diagnosed with ductal carcinoma in-situ
5 December 2024: Study shows huge improvement in progression-free survival with adjuvant rituximab containing therapy. Newly published findings of extended follow-up from a TROG Cancer Research trial of radiotherapy plus chemo-immunotherapy in follicular lymphoma (TROG 99.03 – Follicular lymphoma) provide valuable evidence in support of changing the current standard
24 October 2024: Newly published findings from the ICR-CTSU/2014/10049/TROG 14.02 RAIDER trial offer promise for the use of complex adaptive radiotherapy as an alternative to radical surgery for bladder cancer. The RAIDER team published their significant phase II trial findings in the European Urology journal in October. The trial,
18 September 2024: We’re thrilled to announce the release of globally significant results from the AGITG TOPGEAR study on which TROG collaborated, providing practice-changing evidence about preoperative chemoradiotherapy for gastric cancer. The findings, announced simultaneously at the European Society for Medical Oncology Congress in Barcelona, Spain and published in
The journey to becoming the 200th participant for the TROG 18.01 NINJA Radiation Therapy Trial has been a remarkably quick process for Raymond Terrace resident, Phillip Bambach. Phillip was diagnosed with prostate cancer after he visited his GP for a flu shot. With recent years of the pandemic, he
Findings from the BIG 3-07/TROG 07.01 DCIS Trial (Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study) has been recognised on a global scale in leading medical journal, The Lancet. You can read
The RAVES trial treating prostate cancer Participating in a clinical trial, like the TROG Cancer Research RAVES trial, often means more than just accessing new technology that could increase treatment and quality of life outcomes. For people like James, it’s about using an understandably challenging situation to help others.
Ductal carcinoma in situ (DCIS) of the breast is characterised by abnormal cells in the milk ducts which have not spread into the breast tissue. An international study (BIG 3-07/TROG 07.01) shows that after breast conserving surgery, higher radiation doses to the part of the breast where the DCIS
Paving the way for success in prostate cancer treatment, TROG Cancer Research are helping to reduce common side effects and the length of treatment with the TROG 15.01 SPARK Trial. The clinical trial, led by Professor Paul Keall and Professor Jarad Martin, proposes the use of kilovoltage intrafraction monitoring (KIM) alongside stereotactic body radiotherapy (SBRT) to provide
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Latest News
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292
